🐋 HIMS $2.2M LEAP Call Bet — A Desk Goes Long Telehealth Into 2027

✅ RESOLVED — Next-Day OI Update (2026-06-11): $38C OI 268 → 5,163 (Δ +4,895, even above the print). The bullish LEAP calls opened — contrarian bet is on the books.

Last updated: 2026-06-11

📅 June 10, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

A desk just paid ≈$2.2M for HIMS January-2027 $38 LEAP calls with the stock sitting around $28.60 — a patient, long-dated bullish bet ≈33% out-of-the-money. This is a catalyst-dependent position, not a near-term momentum trade: it needs Hims to re-rate meaningfully higher over the next 7 months. And here's the honest part — the average analyst price target (≈$26.6) sits below both the current price and the strike, so the Street is not yet underwriting a $38 outcome. This desk is betting on something the consensus isn't pricing.

---

📊 Company Overview

Hims & Hers Health (NYSE: HIMS) is a vertically integrated telehealth and consumer-health platform selling subscription treatments across weight loss (GLP-1s / Wegovy), sexual health, dermatology, mental health, hair loss, testosterone, and newer categories like peptides and longevity diagnostics.

• Market Cap: Mid-cap, roughly $6–$7B at current levels (stockanalysis.com, Yahoo Finance)
• Sector: Healthcare — telehealth / digital consumer health
• What changed in 2026: The company exited compounded GLP-1s (after a high-profile Novo Nordisk dispute and settlement), became a branded Wegovy distributor, and completed a $1.15B acquisition of Eucalyptus — transforming from a US weight-loss play into a global consumer-health platform. That strategic pivot is the structural backdrop for a long-dated bullish bet.

---

💰 The Option Flow Breakdown

📊 What Just Happened

At 12:41:29 ET on June 10, 2026, a desk executed a multi-leg auction on HIMS January-2027 $38 calls in two prints hitting nearly simultaneously.

The Tape (June 10, 2026 @ 12:41:29 ET):

Flow type: 🤝 Multi-leg auction (facilitated / price-improvement auction — not a lit sweep, not a block cross).

Key stats:

• 📅 Expiration: January 15, 2027 — roughly 7 months of runway
• 🎯 Strike distance: $38 vs ≈$28.60 spot = ≈33% out-of-the-money
• 💰 Premium paid: ≈$5.65 per contract × ≈5,036 combined tape volume = ≈$2.2M+
• 📊 NBBO aggressor: 75% across (buy-lean) — price execution leaned toward the ask, consistent with a buyer taking the initiative
• 📈 Size vs prior OI: Combined tape volume of ≈5,036+ versus prior open interest of only 268 contracts — size dwarfs the existing OI, which supports an opening read

Note on the two prints: The flow feed showed ≈3,877 total contracts across two prints; the verified tape volume was ≈5,036. The position is at least the feed-visible size and likely larger. Both prints landed within the same second via a multi-leg auction mechanism, meaning the fills were part of a single structured order.

---

⏳ Come back tomorrow (pre-market ≈06:30 ET) for the open/close confirmation.

Combined tape volume (≈5,036) is well above prior OI (268), which strongly supports this being a new opening position — the size difference leaves little room for doubt. That said, next-day OPRA OI will be the definitive test. Expect OI to rise by roughly the net new contracts added. One caveat: if existing holders were on the other side of this auction, next-day OI may rise by less than the full tape volume (a transfer reduces net new OI even though the buy side is opening). If OI rises by a large fraction of 5,036, the open is confirmed. If OI is flat or falls, revisit.

---

🤓 What This Actually Means — Plain English

Let's decode what actually happened here, because the mechanics matter.

This is a long-dated out-of-the-money call purchase — a patient bullish bet.

A LEAP call (options expiring roughly a year or more out) is a way to control 100 shares per contract for a fixed upfront cost, with no obligation to own the stock. By buying the January-2027 $38 calls at $5.65, the desk paid ≈$565 per contract for the right to buy HIMS at $38 any time through January 15, 2027. If HIMS stays below $38, the calls expire worthless. If HIMS rallies above $43.65 (the $38 strike + $5.65 premium paid = breakeven), the position makes money dollar-for-dollar above that level.

Why is this contrarian? Because the average Wall Street analyst price target on HIMS is roughly $26.6 — which sits below the current stock price of ≈$28.60, and far below the $38 strike. That means the consensus is not underwriting the scenario this desk is betting on. Analysts at Bank of America cut their target to $25–$30 after Q1, while even the most bullish Street estimates (JPMorgan at $33, Canaccord at $32) fall short of the strike.

So what IS this desk betting on? A catalyst-driven re-rating over the next 7 months that the Street hasn't yet modeled: the Eucalyptus global platform ramp, two more earnings prints (Q2 ≈August 10, Q3 ≈November), the FDA peptide panel decision that could open a $20B TAM per Canaccord, and continued Wegovy distribution momentum. The LEAP structure gives that thesis time to play out.

Execution mechanism: The fill came via a multi-leg auction — a complex order routed through an exchange price-improvement process. This is not a market-impact panic buy; it's a structured, deliberate entry. The 75% across (buy-lean aggressor) indicates the buyer was willing to pay close to the ask to get the fills done, suggesting some urgency or conviction on timing.

---

📈 Technical Setup / Chart Check-Up

YTD Performance Chart

HIMS has been a volatile story in 2026. The stock started the year under pressure from the GLP-1 / compounding controversy — Novo Nordisk's patent lawsuit filed February 9 and the subsequent DOJ referral hit sentiment hard. The bounce after the March 9 settlement (Hims exited compounding, became a Novo distributor) helped stabilize the stock. The Eucalyptus acquisition close on June 2 is the most recent catalyst, and the stock is currently trading around $28.60–$28.82.

Key observations:

• ⚠️ The year's narrative has been dominated by regulatory and legal overhang — the compounding battle, DOJ referral, and Novo dispute all weighted on the stock
• ✅ The pivot to branded Wegovy distribution and the Eucalyptus close are structural changes that could re-rate the story
• 🎯 Current price is sitting between the $28.0 gamma support and the $30.0 resistance wall — a compressed range heading into a busy catalyst calendar

Gamma-Based Support & Resistance Analysis

The gamma exposure map for HIMS as of June 10, 2026 (current price: $28.82):

🔵 Support Levels (Put Gamma Below Price):

• $28.0 — Moderate support directly below current price. If the stock slips through here, the next level of structural support may require catalyst help to hold.

🟠 Resistance Levels (Call Gamma Above Price):

• $30.0 — Very Strong resistance wall with a meaningful gamma concentration. This is the near-term ceiling to watch. Market makers are short gamma here, meaning rallies toward $30 can create selling pressure as they hedge.

What this means for traders: HIMS is sandwiched in a tight range: $28.0 support vs $30.0 resistance. With the $38 LEAP strike ≈33% above the current resistance wall, near-term gamma is almost irrelevant to the thesis — this trade lives and dies on fundamental catalysts, not technical gamma dynamics. The gamma data is useful for shorter-term traders looking for entry points, but the LEAP buyer needs a structural story, not a gamma-driven squeeze.

Implied Move Analysis

Options market pricing for upcoming expirations (current price ≈$28.83):

• 📅 Weekly (June 12 — 2 days): ±$2.37 (±8.23%) → Range: $26.46 – $31.20
• 📅 Monthly OPEX (July 17 — 37 days): ±$8.44 (±29.28%) → Range: $20.39 – $37.27
• 📅 Quarterly Triple Witch (September 18 — 100 days): ±$14.65 (±50.8%) → Range: $14.18 – $43.48
• 📅 LEAP (January 2028 — 590 days): ±$33.01 (±114.51%) → Range: $0 – $61.84

Translation for regular folks: HIMS options are pricing in enormous uncertainty. An ±8.23% weekly move and ±29.28% monthly move show the market respects this stock's volatility history. The July monthly upper bound at $37.27 is just under the $38 LEAP strike — meaning the options market does see $38 as theoretically reachable within 37 days, but it would require an extreme upside catalyst (like a blowout Q2 earnings or an unexpected FDA announcement). More realistically, the Q3 September implied range ($14.18–$43.48) brackets the $38 strike comfortably on the upside, suggesting the options market assigns meaningful (but not high) probability to $38+ by September.

Key insight: The LEAP buyer paid ≈$5.65 for an option the implied-move math says is reachable but requires above-median outcomes. That's the tradeoff — LEAP calls are "cheap" on a dollar basis versus buying stock, but they require a catalyst event chain to pay off.

---

🎪 Catalysts

✅ Recent Catalysts (Already Occurred)

GLP-1 / Compounding Resolution — March 9, 2026

After a compressed 32-day legal battle, Hims settled with Novo Nordisk on March 9, exiting compounded semaglutide entirely and becoming a branded Wegovy distributor. Hims fulfilled 125,000+ Wegovy shipments within six weeks and is targeting 100,000+ new weight-loss subscribers per month (TradingKey preview). The DOJ referral overhang from Novo's complaint remains unresolved, but the direct litigation risk is removed.

Q1 2026 Earnings — May 2026

Revenue came in at ≈$608M (+≈4% YoY), reflecting the deliberate slowdown from the compounding exit. The market focused on the EPS miss and margin compression. But management raised full-year 2026 guidance to $2.8B–$3.0B with Adjusted EBITDA of $275M–$350M, and gave Q2 2026 guidance of $680M–$700M (≈25–28% growth) — signaling a sharp H2 reacceleration. The guidance raise is the key bull data point.

Eucalyptus Acquisition — Closed June 2, 2026

Hims completed its ≈$1.15B acquisition of Eucalyptus on June 2, 2026, adding operations in Australia, UK, Germany, Japan, and Canada. Combined with prior ZAVA/Livewell acquisitions, this converts Hims into the self-described world's largest consumer-health platform (TipRanks coverage). Funded partly via a $350M convertible notes offering due 2032 — the deal adds leverage and integration risk, but also global revenue diversification.

FDA 503B Closure — April 30, 2026

The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, effectively closing industrial-scale GLP-1 compounding for the entire industry. This removes the competitive threat from future compounder entrants and validates Hims's pivot to branded distribution.

---

🔥 Upcoming Catalysts (The Thesis Drivers)

Q2 2026 Earnings — ≈August 10, 2026 (Critical)

This is the most important near-term event. Guidance called for $680M–$700M in Q2 revenue (≈25–28% growth). A clean beat-and-raise would be the single biggest near-term catalyst to move the stock toward the $38 strike. Watch for: Wegovy subscriber adds, first Eucalyptus revenue contribution, and margin trajectory. (MarketChameleon earnings calendar)

FDA Peptide Panel — Timing Uncertain, High Impact

The FDA signaled in April 2026 it will convene an expert panel to consider loosening restrictions on ≈12 peptides, directly enabling Hims's existing peptide facility and the $20B TAM that Canaccord identified as the next growth vector. A favorable outcome would be a meaningful re-rating catalyst. Timing and outcome are uncertain — this is upside optionality, not a base case.

Eucalyptus Integration & International Ramp — H2 2026

The first proof points on the global platform will surface in Q2/Q3 reporting. Subscriber adds outside the US and early revenue from international markets will determine whether the $1.15B price tag was justified.

Q3 2026 Earnings — ≈November 2026

A second earnings print before the January 2027 expiration gives the thesis two more bites at the apple. If Q2 beats, Q3 needs to follow through to sustain a move toward $38.

---

🎲 Price Targets & Probabilities

Using gamma levels, implied move data, and catalyst roadmap:

📈 Bull Case (15–20% probability)

Target: $38–$43

How we get there: Q2 earnings delivers the guided 25–28% reacceleration with Wegovy adds tracking toward the 100K/month target. Eucalyptus contributes early international revenue. FDA signals progress on the peptide panel. Multiple expands on the global platform re-rating story. Implied move data shows September already brackets $43.48 on the upside — this is possible but requires everything going right.

LEAP economics: $38 calls at $5.65 breakeven at $43.65. If HIMS reaches $48 by January 2027, each contract is worth ≈$1,000 (versus the ≈$565 paid).

🎯 Base Case (55–60% probability)

Target: $25–$35 range (grinding sideways to moderately higher)

The reacceleration delivers modestly, Eucalyptus integration proceeds without major friction, and the stock works from the $28 area toward the $32–$35 range by year-end. The $38 LEAP calls expire worthless or with minimal value. The desk loses most of the ≈$2.2M premium paid. Not a disaster — the position was always a higher-odds catalyst bet, not a base-case trade.

📉 Bear Case (20–25% probability)

Target: $18–$25

Q2 disappoints on margins or subscriber growth, DOJ referral escalates, or Eucalyptus integration stumbles. The stock revisits the pre-settlement lows. The gamma support at $28.0 breaks, and with no structural floor until much lower, a move into the low-$20s or below is plausible. LEAP calls expire worthless.

---

💡 Trading Ideas

🛡️ Conservative: Watch and Wait

Play: No position until Q2 earnings clarity on ≈August 10.

Why this works:

• 📊 The ≈$2.2M LEAP buy is interesting signal, but the implied move (±29% monthly) warns that this stock can move dramatically in both directions
• 💸 Implied volatility is elevated, making any option purchase expensive right now
• 🎯 Better entry: if Q2 delivers the guided 25–28% reacceleration and the stock breaks above $30 resistance on volume, that's a more confirming signal to consider a position
• ⚠️ This is a CONTRARIAN trade vs. Street consensus — respect the caution in analyst targets

Action: Add HIMS to your watchlist. Mark ≈August 10 on your calendar. Let the earnings report do the work.

Risk level: Minimal | Skill level: Beginner-friendly

⚖️ Balanced: Reduced-Size LEAP Calls Post-Q2

Play: After Q2 earnings (if results are strong), buy a smaller LEAP position in a lower-strike option that doesn't require $38 to be profitable.

Structure: After Q2, consider HIMS January-2027 $35 calls (or similar) if IV compresses post-earnings and the stock is showing strength above $32.

Why this works:

• ⏰ Post-earnings IV crush will reduce option premiums substantially, improving entry value
• 🎯 A $35 strike requires ≈22% upside vs today's $38.6% for the $38 — more achievable
• 📊 Still captures the peptide/Eucalyptus/Wegovy thesis but with better risk/reward
• 🛡️ Defined risk — maximum loss is the premium paid

Position sizing: Keep this to 1–3% of portfolio given the speculative nature and 3-star catalyst density.

Risk level: Moderate | Skill level: Intermediate

🚀 Aggressive: Mirror the LEAP (Advanced Only)

Play: Follow the desk into the January-2027 $38 calls at a much smaller scale (5–10 contracts vs. the desk's ≈5,000).

Why this could work:

• 💰 You're paying for the same optionality — two earnings prints, an FDA panel, and a global platform re-rating — for a fraction of the capital
• 🚀 If HIMS reaches $45 by January 2027, each contract (≈$565 cost) is worth ≈$700 (+24% ROI) — but wait for $50 and it's ≈$1,200 per contract (+112% ROI)
• 🎯 Maximum loss is capped at the premium paid — no margin requirements, no unlimited downside

Why this could blow up:

• 😰 Consensus is NOT on board: Average analyst target ≈$26.6 — below the current price. The Street thinks downside risk is more likely than a $38 outcome
• ⏰ Time decay bites: 7 months sounds long, but LEAP options still lose theta daily. If the stock sits flat at $28 for 3 months, your premium will be materially lower
• 💸 Elevated IV: You are buying vol that the market prices as expensive — the ±29% monthly implied move reflects a market that expects big swings, and you're paying for that uncertainty
• ❗ DOJ referral remains open: If the DOJ takes action related to the compounding dispute, this stock could gap down significantly

Breakeven: $43.65 by January 15, 2027.

Risk level: High (premium at full risk) | Skill level: Advanced

---

👥 How Four Different Readers Should Think About This

The same ≈$2.2M LEAP bet means different things depending on who you are. None of this is advice — just framing.

• 🚀 The YOLO trader: A 33%-OTM LEAP on a volatile name is the kind of lottery ticket you're drawn to — but the Street's average target (≈$26.6) sits below today's price, so you'd be betting against consensus on borrowed conviction. If you play it, size it like the lottery ticket it is (a position you can lose entirely), and know the ±29% monthly implied vol means you're paying up for that swing.
• 📈 The swing trader: This is a patient structure, not a swing — January 2027 is 7 months out and the catalysts (Q2 earnings ≈Aug 10, the Eucalyptus integration, a possible FDA peptide panel) are spread across that window. A swing trader watches whether HIMS can first reclaim its recent highs and hold above the gamma resistance before committing; there's no need to chase the desk on day one.
• 💰 The premium collector: The desk paid up for this LEAP — you're the natural counterparty. With implied vol this rich, selling cash-secured puts at lower strikes (e.g. into the $24–26 support zone) collects that elevated premium and only obligates you to own HIMS at a discount you might actually want. Let someone else pay for the long-shot upside.
• 🌱 The beginner: A great trade to study, not copy. Notice the honest tension: a desk with deep pockets is bullish enough to buy 2027 calls, yet the average analyst is bearish relative to the strike. That disagreement is the whole lesson — big institutional money is sometimes early, sometimes wrong, and a LEAP call can bleed to zero even if you're eventually right on direction but wrong on timing. Watch how the August earnings and the OI confirmation play out before risking a dollar.

---

⚠️ Risk Factors

Honest accounting of what could go wrong with a $38 LEAP thesis:

• ❗ DOJ referral is unresolved: Hims was referred to the DOJ by HHS for potential FD&C Act violations related to its oral semaglutide launch. If the DOJ pursues enforcement, the headline risk could be severe — regardless of the underlying legal merits (Buchanan Ingersoll analysis).

• ❗ Street consensus is BELOW spot: The ≈$26.6 consensus target means roughly half the analyst community thinks the stock is already overvalued at current prices. A $38 outcome requires catalysts that are not yet in Street models. This is a faith-in-catalysts bet, not a multiple-expansion story the consensus supports.

• ❗ Margin compression post-compounding-exit: Compounded semaglutide was a high-margin product. Branded Wegovy distribution is lower-margin. Q1 already showed margin pressure; if margins don't recover as Eucalyptus scales and Wegovy volumes grow, the earnings re-rating won't materialize.

• ❗ Eucalyptus integration risk: A $1.15B acquisition funded partly with convertible debt is a meaningful bet. Integration failures — operational, cultural, regulatory — in five international markets simultaneously add execution risk that is difficult to model from the outside.

• ❗ Novo relationship remains fragile: Novo Nordisk has filed 130+ compounding-related lawsuits industry-wide. While Hims is now a distribution partner rather than a target, the relationship between the two companies started as a legal dispute. Any friction in the distribution agreement would directly hit the Wegovy subscriber ramp thesis.

• ❗ Time decay on a 33% OTM position: $38 calls ≈33% out of the money need a significant move just to recover premium. Every week the stock sits near $28–$30 without catalyst progress, theta erodes the position value. The January 2027 expiry provides runway, but it is not infinite patience.

---

🎯 The Bottom Line

Here's the deal: A desk paid ≈$2.2M for HIMS January-2027 $38 LEAP calls when the stock was at $28.60. This is not a near-term momentum trade — it is a patience trade, structured to give a specific set of catalysts time to play out over the next seven months.

The honest picture:

• ✅ The compounding risk is resolved by exit — Hims is no longer a litigation target, it is a Novo Wegovy distribution partner
• ✅ Eucalyptus closed June 2 — the global platform pivot is now a real business, not a plan
• ✅ Q2 guidance implies 25–28% reacceleration — August 10 is the first proof point
• ✅ FDA peptide panel is genuine upside optionality on a $20B TAM
• ❗ But the Street consensus (≈$26.6) sits below both spot and the strike — the desk is betting on outcomes the analyst community is not yet underwriting
• ❗ DOJ referral, margin pressure, Eucalyptus integration risk are real and active

The LEAP call structure is appropriate for this thesis: defined risk (you can only lose the premium paid), long enough runway for two earnings prints plus the FDA decision, and enough leverage to produce meaningful returns if the story re-rates. But it is explicitly a contrarian, catalyst-dependent bet — not a "the chart looks good" trade.

If you're bullish on HIMS: Wait for Q2 earnings on ≈August 10. A clean beat-and-raise with early Eucalyptus contribution and strong Wegovy subscriber data would be the validation signal. Then assess whether the risk/reward justifies a smaller version of this trade.

If you're neutral on HIMS: Watch this space. The $30.0 gamma wall is the near-term ceiling. A sustained break above $30 with catalyst confirmation would shift the technical picture.

Mark your calendar:

• 📅 ≈August 10, 2026 — Q2 2026 earnings (the primary near-term catalyst)
• 📅 H2 2026 — Eucalyptus integration proof points and international subscriber data
• 📅 ≈November 2026 — Q3 2026 earnings (second earnings print before expiry)
• 📅 January 15, 2027 — LEAP expiration

This is a 7-month bet on a company in the middle of a strategic transformation — against a skeptical consensus. Respect both the upside thesis AND the honest risks before following it.

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational purposes only and is not financial advice. The multi-leg auction described here represents a single institutional transaction; it does not imply the trade will be profitable or that retail investors should replicate it. LEAP options can expire worthless, losing 100% of premium paid. The analyst consensus below the current stock price reflects genuine skepticism about the $38 outcome — that skepticism deserves serious weight. Always do your own research and consider consulting a licensed financial advisor before trading.

---

Last updated: June 10, 2026